Trial Profile
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Belapectin (Primary)
- Indications Liver cirrhosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms NASH-CX
- Sponsors Galectin Therapeutics
- 14 Nov 2023 Results assessing to measure the serum galectin-3 in portal hypertension due to nonalcoholic steatohepatitis from NCT01899859 (n=31) and NCT02462967 (n=162) studies, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 14 Nov 2023 Results evaluating multiple creatinine-based eGFR equations in these patients, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 03 Nov 2023 According to a Galectin Therapeutics media release, data from this trial will be presented at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).